Sanders Corazon (Corsee) D. sold $50K of RARE
Sanders Corazon (Corsee) D. sold 2,000 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $25.05 on 2026-06-15.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale of 2,000 shares at $25.05, totaling $50,100, with post-sale holdings of 21,095 shares.
Market read
This provides a fresh ownership-change datapoint but no new fundamental catalyst (no guidance, trial results, or regulatory action).
What to watch
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context on total compensation or prior sales, signal quality is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Ultragenyx Pharmaceutical Inc. (RARE).
Ticker impact
Ultragenyx director Sanders Corazon sold 2,000 shares in an open-market transaction at $25.05 on 2026-06-15 via SEC Form 4.
Low likelihood of sustained price impact; any reaction is likely short-lived unless accompanied by other new catalysts.
The filing is a director open-market sale with no 10b5-1 plan stated; however, insider sales are common and the article provides no new operational/regulatory/clinical information.
Market effects
No sector-level read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
If the sale is not under a 10b5-1 plan (article says “No”), traders may interpret it as higher near-term caution, potentially pressuring the stock briefly.
Key entities
- issuerUltragenyx Pharmaceutical Inc.
Subject of the SEC Form 4 insider transaction disclosure.
- directorSanders Corazon (Corsee) D.
Director who executed the open-market sale.
